Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review.

ABSTRACT:

Background

With the rising burden of cardiovascular disease (CVD) and the need for cost-effective interventions, evaluating the economic implications of Evolocumab becomes crucial.

Objectives

This study aimed to systematically review and evaluate the cost-effectiveness of Evolocumab in adults at risk of CVD.

Methods

We performed an extensive search in Cochrane Library, EMBASE, PubMed, ProQuest, and Web of Science. The reference lists of chosen literature reviews were also examined to find suitable cost-effectiveness analyses (CEAs) of Evolocumab in patients with CVD published until March 2023. The Consolidated Health Economic Evaluation Reporting Standards statement (CHEERS) was used to assess the reporting quality. Cost-related findings were adjusted to reflect 2023

SUBMITTER: Ghadimi N 

PROVIDER: S-EPMC11513655 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature